BBS Pharmaceuticals to be wound up as focus turns to recovering A$3.5m from possible ‘voidable transactions’ by Steve Jones June 7, 2023April 30, 2024 Creditors of failed medicinal cannabis firm BBS Pharmaceuticals have voted to liquidate the company in a […]
Trademark row brews as Cannatrek looks to monopolise ‘T’ branding by Steve Jones June 7, 2023April 30, 2024
Medlab still in limbo as talks continue with ‘interested parties’ by Steve Jones June 7, 2023April 30, 2024
Scrutiny of SAS-B data for psychiatric conditions exposes prescribing ‘disconnect’ by Steve Jones June 7, 2023April 30, 2024
Montu caught in second product dispute over ‘out of stock’ claims by Steve Jones June 7, 2023April 30, 2024
Creso Pharma eyes Australian market as firm seeks GMP licence by Steve Jones June 6, 2023April 30, 2024
‘It all starts with flower’: Tasmanian Botanics takes local road to long-term success by Steve Jones June 5, 2023April 30, 2024
Lennox-Gastaut syndrome becomes second Epidyolex indication to be listed on PBS by Steve Jones June 5, 2023April 30, 2024
Creditors advised to wind up BBS Pharmaceuticals as investigations continue into firm’s financial affairs by Steve Jones June 1, 2023April 30, 2024
Overseas manufacturers in bid to supply non-compliant product for ‘limited period’ beyond July 1 by Steve Jones May 31, 2023April 30, 2024
